<unk>  has shown broad spectrum of activity against a variety of Gram-positive and Gram-negative bacteria, including multi-drug resistant strains, such as methicillin-resistant Staphylococcus aureus (MRSA) and carbapenem-resistant Enterobacteriaceae. It is currently being formulated as for intravenous and oral administration. Spectrum of activity Gram-positive organisms * Staphylococcus aureus (both methicillin-resistant and sensitive strains) * Streptococcus pneumoniae * Enterococcus faecalis * Enterococcus faecium (including vancomycin resistant strains) Gram-negative organisms * Acinetobacter baumannii * Stenotrophomonas maltophilia * Haemophilus influenzae * Moraxella catarrhalis * Neisseria gonorrhoeae * Enterobacteriaceae * Escherichia coli (including ESBL-producing strains) * Klebsiella pneumoniae (including carbapenem resistant strains) * Klebsiella oxytoca * Enterobacter species * Citrobacter species * Proteus mirabilis * Serratia marcescens Similar to other tetracycline derivatives, eravacylcine is poorly active against Pseudomonas aeruginosa with a MIC90 = 16 mcg/mL (range 0.06-64 mcg/mL).<unk>  maintains in-vitro activity against Enterobacteriaceae carrying the mcr-1 gene responsible for polymyxin b/colistin resistance.
Eravacycline
Doxycycline
Sarecycline
Oxytetracycline
Teicoplanin
Omadacycline
Chlortetracycline
Rifampicin